Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V

Inclusion Criteria: * Healthy male and female children * Aged ≥6 to \<36 months on Day 1 * Born at a gestational age ≥37 weeks * Written informed consent * No previous influenza vaccination Exclusion Criteria: * Acute respiratory infection or other acute disease * Acute febrile illness (≥38.0 °C) * Past vaccination with an influenza vaccine, including vaccination against the influenza strain A/California/7/2009 (H1N1)-like virus * Laboratory-confirmed infection with any influenza strain, including the pandemic influenza strain H1N1 (A/California/7/2009 (H1N1)-like virus) * Known hypersensitivity to any vaccine component * Known history of egg protein allergy or severe atopy * Known blood coagulation disorder * Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent for ≥14 days (inhaled or topical steroids are allowed) * Known immunodeficiency (including leukemia, cancer, HIV seropositivity) * Investigational medicinal product received in the past 3 months (90 days) * Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days) * Vaccination with the MMR vaccine in the past 4 weeks, or planned within the study period * Participation in another clinical trial * Child or legal charge of the investigator or an employee at the study site, or living in the same household as the investigator/employee and/or dependent on the investigator/employee * Suspected non-compliance